Oncolytics Biotech Inc. Stock
Oncolytics Biotech Inc. Stock price
Key metrics
| Market capitalization | $49.60m |
| Enterprise Value | $38.19m |
| P/E (TTM) P/E ratio | negative |
| EV/FCF (TTM) EV/FCF | negative |
| P/B ratio (TTM) P/B ratio | 10.45 |
| Revenue (TTM) Revenue | $0.00 |
| EBIT (operating result TTM) EBIT | $-24.44m |
| Free Cash Flow (TTM) Free Cash Flow | $-19.24m |
| Cash position | $12.14m |
Is Oncolytics Biotech Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?
As a Free StocksGuide user, you can view scores for all 6,845 stocks worldwide.
Oncolytics Biotech Inc. Stock Analysis
Analyst Opinions
5 Analysts have issued a Oncolytics Biotech Inc. forecast:
Analyst Opinions
5 Analysts have issued a Oncolytics Biotech Inc. forecast:
Financial data from Oncolytics Biotech Inc.
| Mar '25 |
+/-
%
|
||
| Revenue | - - |
-
|
|
| Gross Profit | - - |
-
|
|
| EBITDA | -24 -24 |
7%
7%
|
EBIT (Operating Income) EBIT | -24 -24 |
7%
7%
|
| Net Profit | -23 -23 |
12%
12%
|
|
In millions USD.
Don't miss a Thing! We will send you all news about Oncolytics Biotech Inc. directly to your mailbox free of charge.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Oncolytics Biotech Inc. Stock News
Company Profile
Oncolytics Biotech, Inc. engages in the development of immuno-oncolytic virus for the treatment of solid tumors and hematological malignancies. It offers a non-pathogenic, properietary isolate of the reovirus that induce selective tumor lysis, and promotes an inflamed tumor phenotype through innate and adaptive immune responses. The company was founded by Matthew C. Coffey and Bradley George Thompson on April 2, 1998 and is headquartered in Calgary, Canada.
| Head office | Canada |
| CEO | Wayne Pisano |
| Employees | 28 |
| Founded | 1998 |
| Website | www.oncolyticsbiotech.com |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
